ArticleFood science & nutrition2026
Edible Bird's Nest Attenuates Neuroinflammation and Cognitive Impairment in a Model of Chronic Fatigue Syndrome.
Article in Food science & nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic fatigue syndrome (CFS) is a debilitating disorder characterized by persistent fatigue with an unclear pathophysiology. Increasing evidence suggests that neuroinflammation plays an important role in the development of CFS; however, the underlying mechanisms remain poorly defined. In this study, we evaluated the effects of edible bird's nest (EBN) in a sleep-deprivation-induced CFS-like mouse model. EBN treatment improved motor and cognitive performance, reduced neuronal necrosis, and preserved synaptic structure in the prefrontal cortex. Blood metabolomic profiling revealed elevated levels of the dipeptide valyl-tryptophan (Val-Trp) following EBN administration. Functional assays showed that Val-Trp attenuates neuroinflammation by suppressing nuclear factor kappa-B signaling, thereby shifting microglia from a pro-inflammatory to a homeostatic state. These findings implicate Val-Trp as a candidate bioactive metabolite associated with the neuroprotective effects of EBN, providing preclinical evidence to support exploration of natural-product-derived interventions for CFS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.